This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ETC-642

Pfizer Inc.

Drug Names(s): RLT Peptide

Description: ETC-642 a complex of a 22-amino acid peptide and phospholipids designed to to mimic HDL and its major protein, apolipoproteinA-I (ApoA-I). HDL is the good cholesterol that removes excess cholesterol and other lipids from artery walls and other tissues.

Deal Structure: In March 1999, Esperion exclusively licensed certain LUV technology from Inex on a worldwide basis. Inex owns granted patents in 13 European countries covering the LUV technology and exclusively licenses, from the University of British Columbia, two issued U.S. patents and one pending U.S. patent application. The European patents claim methods for treatment of atherosclerosis using liposomes. The U.S. patents and patent application claim liposome structure and chemical makeup and methods for treatment of disease, including atherosclerosis. The U.S. patents expire no earlier than 2014. The European patents expire in 2011.

The license agreement with Inex, as amended, requires Esperion to make payments to Inex as milestones are achieved, and to pay Inex royalties on sales of products that are covered by the licensed patents or developed using the licensed technology. This license continues until the later of ten years from the first commercial sale of a product covered by this...See full deal structure in Biomedtracker

Partners: Arbutus Biopharma Corporation


ETC-642 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug